THU-249 The role of the ferroptosis brake glutathione peroxidase 4 in a preclinical model of metabolic dysfunction-associated steatohepatitis
Cédric Peleman(University of Antwerp), Tom Vanden Berghe(University of Antwerp), Annelies Van Eyck(University of Antwerp), Benedicte Y. De Winter(University of Antwerp), Behrouz Hassannia(Albert Einstein College of Medicine), Joris De Man(University of Antwerp), Sven Francque(Inova Health System), Ann Driessen(University of Antwerp), Christophe Van Steenkiste(University of Antwerp), Luisa Vonghia(Antwerp University Hospital), Lieve Vits(University of Antwerp), Emily Van San(University of Antwerp), Geraldine Veeckmans(University of Antwerp), Wilhelmus J. Kwanten(Antwerp University Hospital)
Cited by 0
Related Papers
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Hepatology|2023|2.9k
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Journal of Hepatology|2023|2.7k
EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)
|Journal of Hepatology|2024|1.6k
Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening
|Gastroenterology|2016|1k
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Annals of Hepatology|2023|789